Industry Overview

European brachytherapy market is projected to experience steady growth from $315.6 million in 2025 to $436.7 million by 2035, reflecting a CAGR of 3.3% forecast period (2026-2035). The market is growing, driven by the increasing cancer burden, aging population, and the clinical benefits of brachytherapy as a targeted, minimally invasive treatment. Key market factors include technological advancements like HDR systems, rising government initiatives to expand access to radiotherapy, and the development of new technologies like 3D imaging and AI integration. Despite this, challenges like limited awareness and accessibility in certain regions remain, but are being addressed through strategic expansion and new technology adoption.

Market Dynamics

Rising Incidence and Early Detection Of Localized Cancers

Europe’s ageing population and expanded screening programs are increasing diagnoses of cancers that are well-suited to brachytherapy, notably prostate, gynecological, and certain breast cancers, which increases the eligible patient base for localized radiotherapy solutions. This growing disease burden, together with clinical preference for organ-sparing treatments in early/localized stages, is a primary demand driver for both HDR and LDR brachytherapy systems across major European health markets.

Technological advancements: image-guided, MRI/CT planning, and electronic HDR systems

Rapid improvements in treatment planning and delivery, including CT/MRI-guided brachytherapy, multi-channel applicators, electronic (isotope-free) brachytherapy, and more accurate HDR afterloaders have measurably improved dose conformity, clinical outcomes, and safety. Those advances lower complication rates and increase clinician confidence, accelerating adoption in European oncology centres that prioritise precision radiotherapy.

Favourable Reimbursement & Health-Economics

Many European healthcare systems and payers recognise brachytherapy’s cost-effectiveness for appropriate indications (shorter treatment schedules, fewer hospital visits, reduced late toxicities). Strong public reimbursement frameworks in countries such as Germany, France, and the UK, combined with clinician and patient preference for organ-preserving modalities, make brachytherapy an attractive alternative to prolonged external beam regimens, supporting market uptake.

Market Segmentation

• Based on the indication, the market is segmented into breast cancer, gynecological cancer, prostate cancer, skin cancer, brain cancer, and others.
• Based on the type, the market is segmented into low-dose rate (LDR) brachytherapy and high-dose rate (HDR) brachytherapy.

High-Dose Rate (HDR) brachytherapy Segment to Lead the Market with the Largest Share

The high-dose rate (HDR) brachytherapy segment holds the largest share of the European brachytherapy market and continues to dominate the overall landscape. This dominance is attributed to the growing preference for HDR systems over Low-Dose Rate (LDR) techniques, driven by shorter treatment durations, enhanced precision, and reduced radiation exposure for healthcare workers. HDR brachytherapy allows for outpatient treatment in many indications, lowering hospitalization costs and improving patient convenience. It is increasingly used for managing gynecological, prostate, breast, and skin cancers, which together account for a significant portion of the cancer burden across Europe. Moreover, the availability of advanced HDR afterloaders, image-guided planning, and multi-channel applicators has led to superior treatment outcomes compared to traditional LDR methods. The segment’s expansion is further supported by favorable reimbursement policies and clinical adoption in advanced oncology centers across Germany, France, the UK, and Scandinavia, making HDR brachytherapy the technological and commercial leader in Europe’s brachytherapy market.

Prostate Cancer: Key Segment Driving Market Growth

Among all indications, the prostate cancer brachytherapy segment represents the key driver of market growth within Europe’s brachytherapy sector. Prostate cancer is the most frequently diagnosed malignancy among European men, and brachytherapy has emerged as one of the most effective, minimally invasive treatment modalities for localized disease. HDR and LDR techniques are both widely used in prostate cancer management, but the trend is increasingly shifting toward HDR due to better control rates, reduced rectal toxicity, and greater precision through real-time imaging and dose optimization. The use of 3D imaging, transrectal ultrasound guidance, and computer-assisted planning has significantly enhanced treatment accuracy, resulting in improved patient outcomes and shorter recovery times.

Additionally, the European Association of Urology (EAU) and several national oncology societies have endorsed brachytherapy as a standard treatment option for early-stage prostate cancer, further strengthening its clinical acceptance. Countries like Germany, France, and the UK are leading adopters of prostate brachytherapy owing to robust healthcare infrastructure, high awareness among clinicians, and well-established reimbursement frameworks. Furthermore, as patient preferences shift toward organ-preserving and outpatient procedures, prostate brachytherapy’s advantages such as shorter treatment courses, high cure rates, and minimal side effects are driving significant growth.

Regional Outlook

European brachytherapy market is further divided by countries, including the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe.

Germany Dominates the Market with a Major Share

Germany dominates the European brachytherapy market with a major share, supported by its advanced healthcare infrastructure, early adoption of high-dose rate (HDR) brachytherapy systems, and comprehensive reimbursement framework for cancer treatments. The country’s leadership stems from a strong network of specialized oncology centers, high cancer incidence rates, particularly prostate, gynecological, and breast cancers, and extensive clinical expertise in radiotherapy. German hospitals are at the forefront of implementing image-guided and MRI-based brachytherapy techniques, ensuring precise treatment delivery and improved patient outcomes.

Additionally, the presence of leading manufacturers such as Elekta AB, Varian Medical Systems (Siemens Healthineers), and Eckert & Ziegler BEBIG enhances local innovation and accessibility of advanced technologies. Government support for oncology research, strong collaboration between industry and academic institutions, and consistent investment in digital and automated radiotherapy systems have further solidified Germany’s dominant position. As a result, Germany continues to serve as the primary hub for brachytherapy innovation, training, and clinical excellence across Europe, setting high standards in treatment precision, patient safety, and technological advancement.

Market Players Outlook

The major companies operating in the European brachytherapy market include Becton, Dickinson and Company (BD), Carl Zeiss Meditec AG, Elekta AB, Eckert & Ziegler BEBIG, Varian Medical Systems, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In April 2024, the Industry and Clinical collaboration resulted in a new brachytherapy applicator developed by Maastro, a radiotherapy clinic in the Netherlands, in partnership with Varian. This partially 3D-printed applicator enhances high-dose rate (HDR) brachytherapy for rectal cancer, aiming to reduce quality-of-life risks tied to rectal surgery. Inspired by contact X-ray brachytherapy (CXB) studies, the applicator allows for precise radiation delivery directly to tumors through multiple catheters. It offers a dose range of 60 Gy to over 200 Gy EQD2, maintains tumor contact for uniform dose distribution, and includes a proctoscope for positioning with integrated shielding for normal tissue protection.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the European brachytherapy market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.